NCT06242470 - A Study of MGC026 in Participants With Advanced Solid Tumors | Biotech Hunter

Enrollment

250

Participants

Timeline

Start Date

March 6, 2024

Primary Completion Date

May 31, 2028

Study Completion Date

October 31, 2028

Conditions

Advanced Solid TumorAdvanced CancerMetastatic CancerSquamous Cell Carcinoma of Head and NeckNon Small Cell Lung CancerSmall-cell Lung CancerBladder CancerSarcomaEndometrial CancerMelanomaCastration Resistant Prostatic CancerCervical CancerColorectal CancerGastric CancerGastro-esophageal CancerPancreas CancerClear Cell Renal Cell CarcinomaHepatocellular CarcinomaPlatinum-resistant Ovarian CancerBreast CancerOvarian CancerEsophageal Squamous Cell Cancer (SCC)

Interventions

BIOLOGICAL

MGC026 Dose Escalation

Escalating doses of MGC026

BIOLOGICAL

MGC026 Dose for Expansion

MGC026 recommended dose for expansion

Trial Locations (11)

3084

RECRUITING

Austin Health- Olivia Newton John Cancer Center, Heidelberg

4066

RECRUITING

ICON Cancer Centre Wesley, Auchenflower

5037

RECRUITING

ICON Cancer Centre Kurralta Park, Kurralta Park

49546

RECRUITING

START Midwest, Grand Rapids

77030

RECRUITING

The University of Texas MD Anderson Cancer Center, Houston

RECRUITING

University of Texas Health Science Center at Houston, Houston

84119

RECRUITING

START Mountain Region, West Valley City

90025

RECRUITING

The Angeles Clinic and Research Institute, Los Angeles

97213

RECRUITING

Providence Cancer Institute, Portland

OX3 9DU

RECRUITING

Oxford University Hospitals NHS Foundation Trust, Oxford

SM2 5PT

RECRUITING

The Royal Marsden NHS Foundation Trust, Sutton